Ambrosia Biosciences

What Ambrosia Biosciences does

Ambrosia Biosciences is a clinical-stage biopharmaceutical company founded in 2024 and based in Boulder, Colorado, developing orally bioavailable small molecule therapies for obesity and other metabolic disorders. The company targets Class B GPCRs, a receptor class representing roughly 40% of approved drug targets but with limited oral small molecule options, and is building a four-program pipeline that includes once-daily and once-weekly GLP-1 receptor agonists, a GIP receptor antagonist, and an amylin agonist. Its lead candidate, AMB-702, demonstrated 12.6% placebo-adjusted mean weight loss versus 5.4% for orforglipron in lean non-human primates and is advancing through IND-enabling studies toward a planned Phase 1 initiation in early 2027.

The company's discovery platform integrates cryo-EM-enabled structural biology, biophysical binding assays, AI-powered molecular design, high-throughput screening, and a fully integrated U.S.-based laboratory footprint including a dedicated NMR facility. This stack is operated by a team largely reassembled from the former Array BioPharma Boulder organization (acquired by Pfizer for $11.8 billion in 2019), with scientific leadership credited with 30 prior IND filings, 25 new molecular entities, and 7 FDA approvals. The scientific advisory board includes Richard DiMarchi, a recognized pioneer of GLP-1 therapeutics.

Ambrosia is pre-revenue and monetizes through future commercialization of FDA-approved oral therapies, expected to flow through traditional pharmaceutical distribution including specialty pharmacies, hospital networks, and retail. The company has raised approximately $141 million across a $16M Series A (August 2024), a $25M Series A expansion anchored by Merck's Global Health Innovation Fund (December 2024), and a $100M oversubscribed Series B co-led by Blue Owl Healthcare Opportunities, Redmile Group, and Deep Track Capital (March 2026). Customer focus is on patients requiring accessible, oral, non-injectable treatments for obesity, type 2 diabetes, and related cardiometabolic conditions.

Name

Ambrosia Biosciences

Legal name

Ambrosia Biosciences Inc.

Website

https://ambrosiabiosciences.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Ambrosia Biosciences is a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting Class B GPCRs for obesity and metabolic disorders, with lead GLP-1 receptor agonist AMB-702 advancing toward Phase 1 clinical trials.

Ownership category

akta.pro rank

Product category

Obesity and Cardiometabolic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAAIAH

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Small molecule drug discovery
• Obesity therapeutics
• Cardiometabolic disease
• GLP-1 receptor agonists
• GPCR targeted therapies

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue biopharmaceutical company developing oral small molecule drugs for obesity and metabolic disorders. Revenue will be generated through commercial sales of FDA-approved drugs, targeting the large and growing GLP-1/obesity therapeutics market. Programs include GLP-1R agonist, GIPR antagonist, and amylin agonist candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. Its pipeline targets Class B GPCRs and includes GLP-1R agonists (once-daily and once-weekly dosing), a GIPR antagonist, and an amylin agonist, with lead candidate AMB-702 advancing toward clinical trials. The company integrates cryo-EM structural biology, biophysical binding assays, and AI-powered molecular design within fully integrated U.S.-based biology and chemistry laboratories in Boulder, Colorado.

Product overview

Ambrosia Biosciences is a drug discovery company developing a portfolio of orally delivered, small molecule-based therapies for obesity and other metabolic disorders. The company's pipeline includes four distinct programs targeting Class B GPCRs: GLP-1R agonists (both once-daily and once-weekly formulations), a GIPR antagonist, and an amylin agonist. The lead development candidate, AMB-702, is a novel small molecule GLP-1 receptor agonist with differentiated preclinical data showing superior weight loss compared to orforglipron. The company integrates cryo-EM-enabled structural biology, biophysical binding assays, and AI-powered molecular design to accelerate drug discovery from initial hit to IND.

Differentiator

Problem solved

Functional benefit

Products and services

• GLP-1R Agonist (QD - Once Daily)

Quantifiable outcome

• 12.6% placebo-adjusted mean weight loss after 7 days in lean non-human primates for AMB-702 vs 5.4% for orforglipron at same dose
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Structure Therapeutics: Clinical-stage company developing oral small molecule GLP-1 receptor agonists for obesity and cardiometabolic disease. Directly comparable to Ambrosia's AMB-702 program with similar oral small molecule approach targeting the same Class B GPCR.
• Terns Pharmaceuticals: Clinical-stage biopharma developing oral small molecule therapies for obesity including GLP-1 receptor agonists. Direct competitor in the oral small molecule GLP-1 space with similar therapeutic focus.

Broad incumbents

• Eli Lilly and Company: Leading obesity therapeutics company with orforglipron oral GLP-1 in late-stage clinical trials, alongside injectable Mounjaro/Zepbound. Largest incumbent competing for the same oral GLP-1 market Ambrosia targets.
• Novo Nordisk: Global leader in GLP-1 therapies (Ozempic, Wegovy) and obesity treatment with oral semaglutide approved. Sets the standard for efficacy and commercial scale in the obesity market Ambrosia targets.
• Pfizer: Major pharma with historical oral GLP-1 program (danuglipron) and parent of the Array BioPharma Boulder facility from which Ambrosia's team originated. Competes broadly in cardiometabolic disease.

Emerging players

• Viking Therapeutics: Clinical-stage company developing injectable GLP-1/GIP dual agonists for obesity. Comparable cardiometabolic focus though peptide-based rather than small molecule, competing in the same therapeutic space.
• Septerna: Biotech developing oral small molecule drugs targeting GPCRs using proprietary platform technology. Directly comparable platform approach (GPCR-focused small molecule discovery) with similar target class.
• Metsera: Emerging clinical-stage company developing oral and injectable obesity therapeutics including GLP-1 receptor agonists. Competes in the same oral obesity therapeutics market with similar patient targeting.
• Keros Therapeutics: Clinical-stage company developing therapeutics for metabolic and hematologic diseases. Comparable cardiometabolic focus though targeting different pathways (TGF-beta superfamily); similar stage and investor profile.
• Carmot Therapeutics: Pre-clinical/clinical-stage company developing GLP-1 receptor agonists and other metabolic disease therapies (acquired by Roche). Comparable cardiometabolic focus with both injectable and oral peptide programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ambrosia-biosciences
• Xx.com/ambrosiabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ambrosia Biosciences